Literature DB >> 11405807

Cellular distribution of torsin A and torsin B in normal human brain.

M Konakova1, D P Huynh, W Yong, S M Pulst.   

Abstract

BACKGROUND: Early-onset torsion dystonia is a hyperkinetic movement disorder caused by a deletion of 1 glutamic acid residue in torsin A protein, a novel member of the AAA family of adenosine triphosphatases. No mutation has been found so far in the closely related torsin B protein. Little is known about the molecular basis of the disease, and the cellular functions of torsin proteins remain to be investigated.
OBJECTIVE: To study the regional, cellular, and subcellular distribution of the torsin A and torsin B proteins.
METHODS: Expression of torsin proteins in the central nervous system was analyzed by Western blot analysis and immunohistochemistry in human postmortem brain tissues.
RESULTS: We generated polyclonal antipeptide antibodies directed against human torsin A and torsin B proteins. In Western blot analysis of normal human brain homogenates, the antibodies specifically recognized 38-kd endogenous torsin A and 62-kd endogenous torsin B. Absorption controls showed that labeling was blocked by cognate peptide used for immunization. Immunolocalization studies revealed that torsin A and torsin B were widely expressed throughout the human central nervous system. Both proteins displayed cytoplasmic distribution, although torsin B localization in some neurons was perinuclear. Strong labeling of neuronal processes was detected for both proteins.
CONCLUSIONS: Torsin A and torsin B have similar distribution in the central nervous system, although their subcellular localization is not identical. Strong expression in neuronal processes points to a potential role for torsin proteins in synaptic functioning.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405807     DOI: 10.1001/archneur.58.6.921

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  19 in total

1.  Subtle microstructural changes of the cerebellum in a knock-in mouse model of DYT1 dystonia.

Authors:  Chang-Hyun Song; Doug Bernhard; Ellen J Hess; H A Jinnah
Journal:  Neurobiol Dis       Date:  2013-10-11       Impact factor: 5.996

2.  Dystonia-associated forms of torsinA are deficient in ATPase activity.

Authors:  Marina Konakova; Stefan M Pulst
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia.

Authors:  Chang-Hyun Song; Xueliang Fan; Cicely J Exeter; Ellen J Hess; H A Jinnah
Journal:  Neurobiol Dis       Date:  2012-05-31       Impact factor: 5.996

4.  Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice.

Authors:  Yu Zhao; Michael DeCuypere; Mark S LeDoux
Journal:  Exp Neurol       Date:  2008-01-19       Impact factor: 5.330

5.  Glial elements contribute to stress-induced torsinA expression in the CNS and peripheral nervous system.

Authors:  Y Zhao; J Xiao; M Ueda; Y Wang; M Hines; T S Nowak; M S LeDoux
Journal:  Neuroscience       Date:  2008-05-06       Impact factor: 3.590

Review 6.  The genetics of dystonias.

Authors:  Mark S LeDoux
Journal:  Adv Genet       Date:  2012       Impact factor: 1.944

7.  Cerebellothalamocortical connectivity regulates penetrance in dystonia.

Authors:  Miklos Argyelan; Maren Carbon; Martin Niethammer; Aziz M Ulug; Henning U Voss; Susan B Bressman; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2009-08-05       Impact factor: 6.167

Review 8.  Commentary: Dopaminergic dysfunction in DYT1 dystonia.

Authors:  Thomas Wichmann
Journal:  Exp Neurol       Date:  2008-04-26       Impact factor: 5.330

9.  Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia.

Authors:  Pedro Gonzalez-Alegre; Henry L Paulson
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

Review 10.  Abnormal structure-function relationships in hereditary dystonia.

Authors:  M Carbon; D Eidelberg
Journal:  Neuroscience       Date:  2009-01-01       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.